|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 272.21 USD | -2.06% |
|
-2.42% | -1.10% |
| 01-15 | Trump Launches Health Care Plan to Reduce Drug Costs | MT |
| 01-12 | Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says | RE |
| Capitalization | 72.71B 62.69B 58.36B 54.33B 101B 6,598B 109B 671B 265B 3,147B 273B 267B 11,491B | P/E ratio 2025 * |
11.3x | P/E ratio 2026 * | 10.9x |
|---|---|---|---|---|---|
| Enterprise value | 96.66B 83.33B 77.57B 72.22B 134B 8,770B 145B 892B 352B 4,183B 362B 355B 15,275B | EV / Sales 2025 * |
0.36x | EV / Sales 2026 * | 0.32x |
| Free-Float |
69.07% | Yield 2025 * |
2.15% | Yield 2026 * | 2.24% |
Last Transcript: Cigna
| 1 day | -2.06% | ||
| 1 week | -2.42% | ||
| Current month | -1.10% | ||
| 1 month | -0.60% | ||
| 3 months | -9.04% | ||
| 6 months | -8.74% | ||
| Current year | -1.10% |
| 1 week | 268.95 |  | 279.5 |
| 1 month | 268.8 | | 289.03 |
| Current year | 268.95 | | 289.03 |
| 1 year | 239.51 | | 350 |
| 3 years | 239.51 | | 370.82 |
| 5 years | 191.74 | | 370.82 |
| 10 years | 115.03 | | 370.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Cordani
CEO | Chief Executive Officer | 60 | 01/12/2009 |
Ann Dennison
DFI | Director of Finance/CFO | 55 | 31/03/2025 |
Brian Evanko
DFI | Director of Finance/CFO | 49 | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
David Cordani
CHM | Chairman | 60 | 01/01/2022 |
Eric Foss
BRD | Director/Board Member | 67 | 01/01/2011 |
| Director/Board Member | 66 | 01/01/2018 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 2.33% | 5 M€ | |
| +1.50% | 2.28% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.06% | -2.42% | -4.15% | -13.58% | 72.71B | |
| -2.34% | -3.77% | -35.06% | -31.76% | 300B | |
| -1.85% | +0.55% | -2.70% | -22.06% | 83.31B | |
| -3.76% | -1.29% | -3.31% | -44.28% | 32.87B | |
| -3.22% | -1.85% | -26.51% | -40.38% | 22.49B | |
| -1.21% | +5.45% | -33.13% | -36.06% | 9.84B | |
| 0.00% | +8.28% | +54.32% | +75.64% | 4.5B | |
| +0.86% | -9.15% | +16.76% | -27.33% | 2.11B | |
| Average | -1.70% | -0.52% | -4.22% | -17.48% | 65.96B | |
| Weighted average by Cap. | -2.30% | -2.41% | -22.35% | -28.02% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 271B 233B 217B 202B 376B 24,547B 405B 2,498B 985B 11,709B 1,015B 994B 42,754B | 283B 244B 227B 211B 394B 25,680B 424B 2,613B 1,030B 12,249B 1,061B 1,040B 44,728B |
| Net income | 6.47B 5.57B 5.19B 4.83B 9B 587B 9.68B 59.7B 23.54B 280B 24.25B 23.75B 1,022B | 6.5B 5.61B 5.22B 4.86B 9.05B 590B 9.73B 60.04B 23.67B 281B 24.39B 23.89B 1,028B |
| Net Debt | 23.94B 20.64B 19.21B 17.89B 33.3B 2,172B 35.83B 221B 87.15B 1,036B 89.78B 87.93B 3,784B | 18.74B 16.15B 15.04B 14B 26.07B 1,700B 28.05B 173B 68.21B 811B 70.27B 68.83B 2,961B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 272.21 $ | -2.06% | 1,702,745 |
| 15/01/26 | 277.94 $ | +2.56% | 1,656,823 |
| 14/01/26 | 271.00 $ | -0.30% | 1,822,650 |
| 13/01/26 | 271.81 $ | -1.53% | 1,014,254 |
| 12/01/26 | 276.02 $ | -1.05% | 1,616,634 |
Delayed Quote Nyse, January 17, 2026 at 12:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition